6^th Annual Dementia Congress

Alzheimer’s Disease (AD) is the most prevalent form of dementia, affecting millions worldwide and representing a major challenge for healthcare systems. It is characterized by progressive cognitive decline, memory impairment, and behavioral changes that significantly impact patients’ daily lives and the well-being of their caregivers. This topic will explore the most recent advances in understanding the pathophysiology of AD, including the formation and accumulation of amyloid-beta plaques, neurofibrillary tangles composed of tau proteins, and the role of neuroinflammation in accelerating neuronal loss. Emphasis will be placed on early detection methods, including biomarkers detectable in cerebrospinal fluid and blood, as well as innovative neuroimaging techniques that allow for the identification of disease processes before the onset of clinical symptoms. Participants will also examine emerging pharmacological interventions aimed at slowing disease progression, alongside non-pharmacological strategies such as cognitive stimulation, lifestyle interventions, and multidisciplinary approaches to patient care. Clinical trial outcomes, translational research, and real-world case studies will provide insights into the challenges and opportunities in managing Alzheimer’s Disease. Attendees will benefit from interactive discussions on ethical considerations, patient-centered care, and strategies for improving the quality of life for individuals living with AD. The topic encourages collaboration between neurologists, neuroscientists, clinicians, and researchers, highlighting how scientific discoveries are shaping the next generation of therapies and care models. By integrating clinical insights with research findings, participants will gain a comprehensive understanding of the disease and its impact on patients, families, and healthcare systems, preparing them to contribute meaningfully to advancements in dementia research and care.

Early and accurate diagnosis of dementia is critical for effective treatment planning and patient care. This topic focuses on recent advances in biomarkers, including cerebrospinal fluid, blood-based, and molecular indicators, which enable clinicians to detect pathological changes in the brain before the onset of overt clinical symptoms. Cutting-edge neuroimaging techniques, such as positron emission tomography (PET) and advanced magnetic resonance imaging (MRI), will be discussed for their ability to visualize structural and functional changes associated with neurodegenerative diseases. The role of artificial intelligence and machine learning in analyzing complex imaging data will be highlighted, showing how technology can enhance diagnostic precision, predict disease progression, and support personalized medicine approaches. Attendees will explore multi-modal diagnostic strategies that integrate biomarkers, neuroimaging, and cognitive assessments to create individualized profiles for patients, allowing for timely intervention and improved outcomes. Case studies, clinical experiences, and ongoing research projects will be presented to illustrate the practical application of these diagnostic tools. The topic emphasizes the importance of collaborative approaches between researchers, clinicians, and technologists to translate laboratory discoveries into clinical practice. By understanding the latest trends and innovations in early diagnosis, participants will be better equipped to identify at-risk populations, monitor disease progression, and contribute to the development of more effective therapeutic interventions.

Understanding the molecular and cellular mechanisms underlying dementia is essential for the development of new therapeutic strategies. This topic examines the biological processes contributing to neurodegeneration, including protein misfolding, synaptic dysfunction, mitochondrial impairment, oxidative stress, and neuroinflammatory pathways. Attendees will learn about experimental models, including cellular and animal systems, which provide insights into disease mechanisms and enable preclinical testing of potential treatments. Recent advances in genomics, proteomics, and transcriptomics will be explored, demonstrating how high-throughput technologies are uncovering new molecular targets and pathways relevant to various forms of dementia. Emphasis will also be placed on translational research, illustrating how discoveries in the laboratory are being applied to clinical practice to improve diagnosis, treatment, and patient outcomes. Discussions will highlight the importance of interdisciplinary collaboration between basic scientists, clinical researchers, and healthcare professionals in accelerating therapeutic development. Participants will gain a comprehensive understanding of how molecular insights can inform drug discovery, personalized medicine, and innovative care approaches. By connecting foundational research with clinical application, attendees will be empowered to contribute to the next generation of dementia therapies and enhance the overall understanding of neurodegenerative diseases.

Genetic and genomic research has become a cornerstone in understanding the risk factors, progression, and potential therapeutic targets for dementia. This topic will explore the latest discoveries in familial and sporadic forms of dementia, including mutations in genes such as APP, PSEN1, PSEN2, and APOE, and their implications for disease onset and severity. Advances in genome-wide association studies (GWAS) and next-generation sequencing technologies are uncovering novel genetic variants and pathways that contribute to neurodegeneration. The role of epigenetics, gene-environment interactions, and regulatory mechanisms in influencing disease susceptibility and progression will also be discussed. Participants will gain insights into how these discoveries are being translated into personalized medicine approaches, enabling tailored prevention and treatment strategies for at-risk individuals. Cutting-edge research on polygenic risk scores, functional genomics, and CRISPR-based interventions will be highlighted as potential tools to modify disease trajectory. Emphasis will be placed on collaborative efforts between geneticists, neurologists, and clinical researchers to bridge the gap between laboratory findings and practical applications. This topic encourages discussion on ethical considerations surrounding genetic testing, data privacy, and implications for families and caregivers. By understanding the molecular underpinnings of dementia through genetic and genomic perspectives, participants will be equipped to integrate these insights into research, clinical practice, and the development of next-generation therapies that target the root causes of neurodegeneration.

Developing effective therapies that can modify the progression of dementia is a central goal in neurology and neuroscience. This topic will provide a comprehensive overview of current and emerging pharmacological interventions designed to slow or halt disease progression rather than only addressing symptoms. Discussions will cover mechanisms of action, including targeting amyloid-beta accumulation, tau pathology, neuroinflammation, and synaptic dysfunction. Participants will examine preclinical and clinical trial data, highlighting successes, limitations, and lessons learned from past and ongoing studies. The session will also explore innovative approaches such as gene therapy, immunotherapy, and small molecule drugs that aim to correct underlying molecular and cellular abnormalities. Attention will be given to challenges in translating laboratory findings into clinical applications, including issues related to drug delivery, safety, efficacy, and patient selection. Collaborative strategies between academic institutions, pharmaceutical companies, and regulatory agencies will be emphasized to accelerate therapeutic development. Attendees will gain insights into personalized treatment approaches and precision medicine strategies that target specific patient populations based on biomarkers, genetic profiles, and disease stage. This topic aims to equip researchers, clinicians, and industry professionals with the knowledge needed to contribute to the next generation of disease-modifying therapies and improve outcomes for individuals affected by dementia.

Translating discoveries from basic science into effective therapies requires robust clinical trial design and careful implementation. This topic will focus on the methodology, design, and outcomes of clinical trials in dementia research, highlighting recent advances and ongoing studies. Participants will learn about recruitment strategies, patient stratification based on biomarkers and genetic profiles, and innovative trial designs such as adaptive and platform trials. The session will emphasize the importance of integrating preclinical findings with clinical applications, ensuring that experimental therapies are evaluated rigorously for safety and efficacy. Key challenges such as placebo effects, trial duration, endpoints, and regulatory considerations will be addressed, along with strategies to improve trial success rates. Collaborative networks, international consortia, and partnerships between academia, industry, and healthcare institutions will be discussed as essential elements for advancing translational research. Attendees will gain practical insights into monitoring therapeutic effects, evaluating cognitive outcomes, and implementing patient-centered approaches in clinical studies. By connecting laboratory discoveries with clinical interventions, participants will be empowered to contribute to the development of innovative therapies and accelerate progress toward effective dementia care

Aging is the greatest risk factor for dementia, and understanding the mechanisms of neurodegeneration in aging brains is critical for prevention and treatment. This topic will explore cellular and molecular processes that occur during normal aging and how they intersect with pathological changes in dementia, including protein aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation. Participants will examine the impact of vascular factors, metabolic changes, and lifestyle influences on cognitive decline, highlighting the interplay between systemic health and brain function. Recent research on neuroplasticity, synaptic resilience, and neuroprotective strategies will be discussed, providing insights into potential interventions to slow or prevent neurodegeneration. Emphasis will be placed on translational approaches, including how animal and cellular models of aging inform clinical strategies, and the development of biomarkers to distinguish normal aging from early-stage dementia. Attendees will gain knowledge about emerging therapeutic targets, lifestyle interventions, and multidisciplinary approaches to support healthy cognitive aging, ultimately contributing to improved prevention strategies and personalized care for older adults at risk of dementia.

Cognitive decline and memory impairment are central features of dementia, and understanding these deficits is essential for diagnosis, intervention, and rehabilitation. This topic will cover the spectrum of cognitive and behavioral changes observed in dementia, including deficits in attention, executive function, language, and visuospatial abilities. Neuropsychological assessments, standardized testing, and innovative digital tools for cognitive evaluation will be highlighted, providing practical approaches to monitor disease progression and treatment efficacy. Participants will learn about the neural correlates of memory and cognition, including hippocampal atrophy, network dysfunction, and disrupted connectivity. Interventions to enhance cognitive function, including cognitive training, rehabilitation strategies, pharmacological support, and lifestyle modifications, will be discussed. Special attention will be given to individualized assessment and management plans, addressing the variability in cognitive decline among patients. By integrating clinical, neuropsychological, and research perspectives, attendees will gain a holistic understanding of memory disorders and the tools necessary to improve diagnostic accuracy, therapeutic planning, and patient outcomes.

Digital health technologies and artificial intelligence are transforming dementia care, offering novel tools for diagnosis, monitoring, and intervention. This topic will explore wearable devices, remote monitoring systems, mobile applications, and AI-driven algorithms that assess cognitive function, detect behavioral changes, and predict disease progression. Participants will learn about the use of machine learning and big data analytics to identify patterns in clinical and neuroimaging data, facilitating early diagnosis and personalized care. Ethical considerations, data privacy, and user-centered design will also be discussed to ensure safe and effective implementation. The session will highlight telemedicine platforms, virtual reality interventions, and assistive technologies that enhance patient independence and caregiver support. Attendees will gain insights into the integration of technology with traditional clinical care, fostering innovative approaches that improve outcomes, efficiency, and quality of life for individuals living with dementia.

International collaboration is essential for advancing dementia research and care. This topic will focus on global initiatives, consortia, and partnerships aimed at accelerating scientific discovery, standardizing diagnostic criteria, and sharing best practices across countries. Participants will learn about large-scale cohort studies, multicenter clinical trials, and public-private partnerships that promote innovation and knowledge exchange. Emphasis will be placed on collaborative strategies for data sharing, capacity building, and policy advocacy to address the growing global burden of dementia. Attendees will gain insights into opportunities for international collaboration, networking, and participation in initiatives that drive progress in research, prevention, and patient-centered care.

Effective care models are essential to support individuals living with dementia and their families. This topic will explore multidisciplinary approaches, including medical, psychological, social, and rehabilitative strategies that promote functional independence, safety, and quality of life. Participants will learn about structured rehabilitation programs, occupational therapy, cognitive stimulation, and caregiver support initiatives. Discussions will include residential and community-based care, integration of healthcare services, and innovations in long-term care delivery. Emphasis will be placed on person-centered approaches, ethical decision-making, and strategies to engage patients and families in care planning. Attendees will gain insights into best practices, challenges, and innovative models that enhance dementia care outcomes and foster collaborative, sustainable support systems.

Behavioral and psychological symptoms are common in dementia and can significantly impact patients and caregivers. This topic will focus on the assessment, management, and intervention strategies for agitation, depression, anxiety, psychosis, and sleep disturbances. Participants will explore pharmacological and non-pharmacological treatments, including behavioral therapy, environmental modifications, and caregiver training. The session will also discuss the neurobiological basis of these symptoms, highlighting the interplay between cognitive decline, brain changes, and emotional regulation. Attendees will gain practical knowledge to develop individualized care plans, improve patient outcomes, and support caregiver well-being while addressing ethical considerations in symptom management.

Dementia poses significant societal challenges, making public health strategies and policy frameworks critical. This topic will explore risk reduction strategies, preventive interventions, and awareness campaigns aimed at delaying or preventing cognitive decline. Participants will learn about population-based studies, lifestyle interventions, educational programs, and health policy initiatives designed to support individuals at risk. The session will highlight global perspectives, health system preparedness, and the role of policymakers, healthcare providers, and advocacy groups in shaping effective dementia strategies. Attendees will gain insights into scalable interventions and policies that promote early detection, access to care, and improved quality of life for affected populations.

Ethical considerations are central to dementia care, particularly in decision-making, autonomy, consent, and end-of-life planning. This topic will examine strategies to ensure patient-centered care, balancing clinical needs with respect for individual values and preferences. Participants will discuss approaches to advance care planning, shared decision-making, and communication with patients and caregivers. Quality of life metrics, psychosocial support, and interventions that enhance dignity and independence will be highlighted. The session emphasizes ethical frameworks, interdisciplinary collaboration, and culturally sensitive approaches to provide compassionate and effective care, empowering participants to integrate ethical principles into clinical and research practice.

This topic will focus on the latest innovations and future directions in dementia research, highlighting promising therapeutic targets, technological advancements, and integrative care approaches. Participants will explore breakthroughs in genomics, biomarker discovery, neuroimaging, digital health, and precision medicine. Emphasis will be placed on translational research, clinical trial innovations, and collaborative networks that accelerate discovery and application. Attendees will gain insights into global research initiatives, emerging methodologies, and multidisciplinary strategies designed to improve diagnosis, treatment, and patient care. By understanding current trends and anticipating future developments, participants will be equipped to contribute to the evolving field of dementia research and care.

Lifestyle factors, including nutrition, physical activity, and social engagement, play a crucial role in brain health and the prevention of cognitive decline. This topic will explore the impact of dietary patterns, such as the Mediterranean and MIND diets, on reducing dementia risk and slowing progression. Participants will also learn about the benefits of regular exercise, mental stimulation, stress management, and sleep hygiene on cognitive function. Discussions will include clinical studies, population-based research, and practical strategies for implementing lifestyle interventions in community and clinical settings. Emphasis will be placed on personalized recommendations, combining lifestyle, genetic, and biomarker information to promote long-term brain health. Attendees will gain insights into integrating preventive strategies into daily routines and public health programs, enhancing cognitive resilience and improving quality of life for individuals at risk of or living with dementia.

Caregivers are essential partners in dementia management, and their well-being directly impacts patient outcomes. This topic will focus on education, training, and support programs for family and professional caregivers. Participants will explore strategies for managing caregiver stress, burnout, and mental health challenges, as well as tools for improving communication, problem-solving, and patient engagement. Evidence-based interventions, peer support networks, and digital resources will be discussed to empower caregivers in their role. The session will also highlight the importance of culturally sensitive approaches and policies that provide accessible support systems. Attendees will gain practical knowledge to implement effective caregiver programs and enhance both patient and caregiver quality of life.

Neuroinflammation and immune dysregulation are increasingly recognized as critical contributors to dementia pathogenesis. This topic will examine the molecular and cellular mechanisms of neuroinflammation, including microglial activation, cytokine signaling, and blood-brain barrier dysfunction. Participants will learn about the role of systemic inflammation, immune senescence, and peripheral immune interactions in cognitive decline. Emerging therapeutic approaches targeting immune pathways, including immunomodulatory drugs and biologics, will be highlighted. The session will also discuss translational studies that bridge basic immunology research with clinical applications, providing insights into novel strategies to mitigate neurodegeneration. Attendees will gain an integrated understanding of immune mechanisms in dementia and their potential for therapeutic intervention.

Sleep disturbances and circadian rhythm disruptions are common in dementia and can accelerate cognitive decline. This topic will explore the relationship between sleep architecture, melatonin regulation, and neurodegenerative processes. Participants will examine evidence linking poor sleep quality, insomnia, and sleep apnea to amyloid accumulation, tau pathology, and neuroinflammation. Strategies for assessing and managing sleep disturbances in patients, including behavioral, pharmacological, and technological interventions, will be discussed. The session will highlight the importance of early identification and treatment of sleep disorders to improve cognitive outcomes, quality of life, and overall brain health. Attendees will gain practical guidance for integrating sleep management into dementia care plans.